AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
Study NCT02704962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full-dose olanzapine
Description: trifluoperazine 5mg/d
Study NCT00787111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine (prozac)
Description: Formulation: ODT
Study NCT03429218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0184
Description: Oral dose once weekly for 4 weeks
Study NCT00162773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
Study NCT03588468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
Study NCT01603147 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline 225 ml
Study NCT01603147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch-mAb7f9
Description: The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
Study NCT00487591 — intervention group
Intervention type: DRUG
Intervention: Omacor (omega-3-acid ethyl esters)plus simvastatin
Description: Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
Study NCT00487591 — intervention group
Intervention type: DRUG
Intervention: simvastatin plus placebo
Description: simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
Study NCT01400048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aloe vera effervescent tablet (AVH200)
Description: 250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
Study NCT01400048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 60mg Ascorbic acid
Study NCT00250484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
Study NCT00250484 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
Study NCT01961492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: A single fecal microbiota transplantation through colonoscope
Study NCT04464460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671
Description: TAK-671 intravenous infusion.
Study NCT04464460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671 Placebo
Description: TAK-671 placebo-matching intravenous infusion.
Study NCT02324543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle
Study NCT02324543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle
Study NCT02324543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle
Study NCT03286504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANMI - Cohort Care
Description: FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
Study NCT06255483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction
Description: A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node .
Study NCT01965795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Coffee Fruit Concentrate (WCFC)
Description: Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
Study NCT01965795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrim
Description: Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
Study NCT03137368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane Tablets
Description: drug therapy
Study NCT03137368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ovarian function suppression/ablation
Description: Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
Study NCT03137368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ovarian function suppression/ablation
Description: Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
Study NCT03137368 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6*10 gene test
Description: CYP2D6\*10 gene test
Study NCT03137368 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2D6*10 gene test
Description: CYP2D6\*10 gene test
Study NCT03137368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: drug therapy
Study NCT01007877 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
Study NCT01007877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
Study NCT01007877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
Study NCT02321904 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal Confocal Microscopy
Description: Close-up pictures of the front part of the eye (the cornea)
Study NCT02321904 — intervention group
Intervention type: PROCEDURE
Intervention: Nerve Conduction Studies
Description: The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
Study NCT00162773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150-375 milligrams depending on body weight and serum IgE.
Study NCT02321904 — intervention group
Intervention type: PROCEDURE
Intervention: Quantitative sensory testing
Description: Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
Study NCT02321904 — intervention group
Intervention type: PROCEDURE
Intervention: Neuropathy Symptom Score
Description: A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
Study NCT02493179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serodase 5 mg
Description: Serodase 5mg two tablets three times per day
Study NCT02493179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets three times per day
Study NCT02321904 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical nerve examination
Description: Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
Study NCT02756520 — intervention group
Intervention type: OTHER
Intervention: Observational study: Supplemented protein-restricted diet
Description: Observational study: Supplemented protein-restricted diet
Study NCT02497014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Stent
Description: Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
Study NCT02497014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 Stents
Description: Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion.
Study NCT01255020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-Keto Acid with restricted protein diet
Description: α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d
Study NCT01255020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus restricted protein diet
Description: placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d.
Study NCT03974009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcaneal taping
Description: Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
Study NCT03974009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham taping
Description: Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
Study NCT03974009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
Study NCT03974009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
Study NCT04182893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA and Exosome Combined Detection
Description: Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
Study NCT00092729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663)
Description: Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study NCT00092729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study NCT00092729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: naproxen sodium
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study NCT01708603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC
Study NCT01708603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered SC
Study NCT01708603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered SC
Study NCT01708603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
Study NCT01708603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered SC
Study NCT04412304 — intervention group
Intervention type: DRUG
Intervention: Dose of Tinzaparin or Dalteparin
Description: The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
Study NCT04403282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine Topical
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Study NCT04403282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eflornithine Topical
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Study NCT03942731 — intervention group
Intervention type: OTHER
Intervention: Behavioral allergy testing protocol
Description: skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
Study NCT01617213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 200 mg/m2/IV
Study NCT01617213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
Study NCT00313170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg \& 500 mg
Study NCT00358488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK159797 (10, 15, and 20mcg)
Description: GSK159797 (10, 15, and 20mcg)
Study NCT00358488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: salbutamol
Study NCT00358488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol 50mcg
Description: salmeterol 50mcg
Study NCT00358488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05419440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic drainage of appendicular abscess
Description: access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
Study NCT04286880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003.
Study NCT04286880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
Study NCT02818543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937
Study NCT02324543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV on days 4 and 11 of a 21 day cycle
Study NCT01745003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
Study NCT05896345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
Study NCT05896345 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SWL and ODT
Description: Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
Study NCT03840876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEI NASAL JET (WNJ)
Description: Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
Study NCT02355301 — intervention group
Intervention type: PROCEDURE
Intervention: orthopedic
Description: Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)